![Late last year, Eli Lilly shared disappointing results of a late-stage clinical trial of its experimental drug ...](/web/20170207063719im_/http://www.smh.com.au/content/dam/images/g/h/m/a/p/3/image.related.wideLandscape.460x259.gu6wjx.png/1486418348580.jpg)
Billions spent, a 99% failure rate and no 'magic bullet'
Despite a 99 per cent failure rate and a recent setback, Alzheimer's researchers are plowing ahead with hundreds of experiments - and a boost in US federal money - to try to crack a deadly disease that has flummoxed them for decades.